Pharmacotherapy
ApprovedSmall molecule
Pharmacotherapy is one of 232 small molecule programs targeting Endothelial Dysfunction. It is currently in Approved.
7
Indications
15
Total Trials
3
Active Trials
231
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
271 competitors in Allergic Rhinitis
#DrugCompanyPhaseTrials
1Asmanex Hfa
PPerrigo Company
Phase 3
Pharmacotherapy
UUniversity of Pittsburgh
Approved
Sudafed
KKenvue Brands
Phase 3
Flovent
PParatek Pharmaceuticals Inc
Phase 3
Kenalog
BBassett Healthcare
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Active Comparator
ModernaPhase 3
Immunotherapy
Bristol-Myers SquibbPhase 3
Allegra-D
PfizerPhase 3
Asmanex
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Bruxism1 trial
A Comparative Study of EMG Biofeedback and Pharmacotherapy for the Treatment of Masticatory Muscle Hyperactivity in Bruxism Patients
Not yet recruiting·—·N/A·NCT06894472·30 enrolled
Coronary Artery Bypass1 trial
Allergic Rhinitis1 trial
Distinct Response of CD4+CD25+Foxp3+ and IL-10-secreting Type I T Regulatory Cells to Cluster Specific Immunotherapy in Allergic Rhinitis Children
Completed·—·N/A·NCT01291381·50 enrolled
10 more indications
Alzheimer disease1 trial
Long-term Effect of θ Burst Magnetic Stimulation on Clinical Symptoms of Alzheimer Disease
Completed·—·N/A·NCT04754152·45 enrolled
Chronic Pelvic Pain1 trial
Major Depression1 trial
Endothelial Dysfunction1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pharmacotherapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity of Pittsburgh